Review



software version 7.10.3  (MetaMorph Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MetaMorph Inc software version 7.10.3
    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left <t>ventricular</t> end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.
    Software Version 7.10.3, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/software+version+7%2E10%2E3/version+7+10+5+software/pmc11745812-64-16-21
    Average 90 stars, based on 1 article reviews
    software version 7.10.3 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy"

    Article Title: Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy

    Journal: Regenerative Therapy

    doi: 10.1016/j.reth.2024.12.008

    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.
    Figure Legend Snippet: Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.

    Techniques Used: Control

    Related Articles

    Control:

    Article Title: Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy
    Article Snippet: The fibrotic area was calculated as the ratio of the total fibrotic area to the total left ventricular area using the MetaMorph software (version 7.10.3).



    Similar Products

    software version 7.10.3  (MetaMorph Inc)
    90
    MetaMorph Inc software version 7.10.3
    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left <t>ventricular</t> end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.
    Software Version 7.10.3, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/software+version+7%2E10%2E3/version+7+10+5+software/pmc11745812-64-16-21
    Average 90 stars, based on 1 article reviews
    software version 7.10.3 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.

    Journal: Regenerative Therapy

    Article Title: Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy

    doi: 10.1016/j.reth.2024.12.008

    Figure Lengend Snippet: Systemic administration of iPS-MSCs improves cardiac function in a rat ischemic cardiomyopathy model. (a) Representative images of M-mode echocardiography in the control group, iPS-MSC group, and siAlix-MSC group. (b) Ejection fraction (EF), left ventricular end-diastolic diameter (LVDd), and left ventricular end-diastolic diameter (LVD) before and 1 week after sequential administration of cells in each group (control group, n = 10; iPS-MSC group, n = 12; siAlix-MSC group; n = 9). Data are presented as mean ± SD. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001 between groups, by one-way analysis of variance with post hoc Turkey's multiple comparisons.

    Article Snippet: The fibrotic area was calculated as the ratio of the total fibrotic area to the total left ventricular area using the MetaMorph software (version 7.10.3).

    Techniques: Control